Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 378

1.

Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.

Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA.

J Am Heart Assoc. 2018 Jan 4;7(1). pii: e006940. doi: 10.1161/JAHA.117.006940.

2.

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.

Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P; ASCOT Investigators.

Lancet. 2017 Jun 24;389(10088):2473-2481. doi: 10.1016/S0140-6736(17)31075-9. Epub 2017 May 2.

3.

Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study.

Mancusi C, Gerdts E, de Simone G, Midtbø H, Lønnebakken MT, Boman K, Wachtell K, Dahlöf B, Devereux RB.

Blood Press. 2017 Jun;26(3):150-155. doi: 10.1080/08037051.2016.1243009. Epub 2016 Nov 24.

PMID:
27710139
4.

Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy.

Weber MA, Bloch M, Bakris GL, Weir MR, Zappe DH, Dahlof B, Velazquez EJ, Pitt B, Basile JN, Jamerson K, Hua TA.

J Clin Hypertens (Greenwich). 2016 Apr;18(4):299-307. doi: 10.1111/jch.12816. Epub 2016 Mar 28.

5.

Angiotensin AT2-receptor stimulation improves survival and neurological outcome after experimental stroke in mice.

Schwengel K, Namsolleck P, Lucht K, Clausen BH, Lambertsen KL, Valero-Esquitino V, Thöne-Reineke C, Müller S, Widdop RE, Denton KM, Horiuchi M, Iwai M, Boato F, Dahlöf B, Hallberg A, Unger T, Steckelings UM.

J Mol Med (Berl). 2016 Aug;94(8):957-66. doi: 10.1007/s00109-016-1406-3. Epub 2016 Mar 16.

PMID:
26983606
6.

Physical activity and exercise lower blood pressure in individuals with hypertension: narrative review of 27 RCTs.

Börjesson M, Onerup A, Lundqvist S, Dahlöf B.

Br J Sports Med. 2016 Mar;50(6):356-61. doi: 10.1136/bjsports-2015-095786. Epub 2016 Jan 19. Review.

PMID:
26787705
7.

[Aerobic physical activity lowers blood pressure in hypertension].

Börjesson M, Onerup A, Lundqvist S, Dahlöf B.

Lakartidningen. 2015 Nov 17;112. pii: DRAI. Review. Swedish.

8.

Left Ventricular Wall Stress-Mass-Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients: LIFE Study.

Devereux RB, Bang CN, Roman MJ, Palmieri V, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Wachtell K, Hille DA, Dahlöf B.

Hypertension. 2015 Nov;66(5):945-53. doi: 10.1161/HYPERTENSIONAHA.114.05582. Epub 2015 Sep 21.

PMID:
26418019
9.

Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.

Vishram JK, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Mancia G, Okin PM, Rothwell PM, Wachtell K, Olsen MH.

J Hypertens. 2015 Dec;33(12):2422-30. doi: 10.1097/HJH.0000000000000739.

PMID:
26378687
10.

Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients.

Okin PM, Hille DA, Larstorp AC, Wachtell K, Kjeldsen SE, Dahlöf B, Devereux RB.

Hypertension. 2015 Aug;66(2):368-73. doi: 10.1161/HYPERTENSIONAHA.115.05728. Epub 2015 Jun 8.

PMID:
26056336
11.

Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.

Okin PM, Hille DA, Wachtell K, Kjeldsen SE, Boman K, Dahlöf B, Devereux RB.

J Hypertens. 2015 Jul;33(7):1480-6. doi: 10.1097/HJH.0000000000000559.

PMID:
25799208
12.

Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial.

Skoglund PH, Svensson P, Asp J, Dahlöf B, Kjeldsen SE, Jamerson KA, Weber MA, Jia Y, Zappe DH, Östergren J; ACCOMPLISH investigators.

J Clin Hypertens (Greenwich). 2015 Feb;17(2):141-6. doi: 10.1111/jch.12460. Epub 2014 Dec 22.

13.

Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.

Okin PM, Wachtell K, Gerdts E, Dahlöf B, Devereux RB.

J Hypertens. 2014 Dec;32(12):2472-8; discussion 2478. doi: 10.1097/HJH.0000000000000432.

PMID:
25340854
14.

Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats.

Castoldi G, di Gioia CR, Bombardi C, Maestroni S, Carletti R, Steckelings UM, Dahlöf B, Unger T, Zerbini G, Stella A.

Am J Physiol Renal Physiol. 2014 Nov 15;307(10):F1123-31. doi: 10.1152/ajprenal.00247.2014. Epub 2014 Sep 3.

15.

Physician (investigator) inertia in apparent treatment-resistant hypertension - insights from large randomized clinical trials. Lennart Hansson Memorial Lecture.

Kjeldsen SE, Julius S, Dahlöf B, Weber MA.

Blood Press. 2015 Feb;24(1):1-6. doi: 10.3109/08037051.2014.946787. Epub 2014 Aug 27.

PMID:
25162203
16.

Direct angiotensin type 2 receptor (AT2R) stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice.

Valero-Esquitino V, Lucht K, Namsolleck P, Monnet-Tschudi F, Stubbe T, Lucht F, Liu M, Ebner F, Brandt C, Danyel LA, Villela DC, Paulis L, Thoene-Reineke C, Dahlöf B, Hallberg A, Unger T, Sumners C, Steckelings UM.

Clin Sci (Lond). 2015 Jan;128(2):95-109. doi: 10.1042/CS20130601.

PMID:
25052203
17.

Blood pressure measurement reliability among different racial-ethnic groups in a stroke prevention study.

Estol CJ, Bath PM, Gorelick PB, Cotton D, Martin RH, Weber MA, Dahlof B; PRoFESS Publications Committee; PRoFESS Investigators.

Blood Press Monit. 2014 Oct;19(5):256-62. doi: 10.1097/MBP.0000000000000045.

PMID:
24736279
18.

Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.

Bang CN, Gerdts E, Aurigemma GP, Boman K, de Simone G, Dahlöf B, Køber L, Wachtell K, Devereux RB.

Circ Cardiovasc Imaging. 2014 May;7(3):422-9. doi: 10.1161/CIRCIMAGING.113.001275. Epub 2014 Apr 10.

PMID:
24723582
19.

Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).

Mancusi C, Gerdts E, De Simone G, Abdelhai YM, Lønnebakken MT, Boman K, Wachtell K, Dahlöf B, Devereux RB.

Blood Press. 2014 Aug;23(4):206-12. doi: 10.3109/08037051.2013.858482. Epub 2014 Feb 24.

PMID:
24564262
20.

Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy.

Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Julius S, Dahlöf B, Devereux RB.

Am J Hypertens. 2014 Jul;27(7):966-72. doi: 10.1093/ajh/hpu006. Epub 2014 Feb 19.

PMID:
24552888

Supplemental Content

Loading ...
Support Center